“We are planning an additional phase three study for PADCEP. It'll start later this year.”

In context

“Louise. And, clearly, Seagen has been integrated on research, commercial, manufacturing, and multiple other levels. But, given that Chris was the leader that drove the integration, during the first sensitive year Chris, maybe you want to make a comment on how the integration of Seagen went and continued. Chris Boshoff: Thank you very much for the question. So firstly, we have a vibrant community of scientists and clinicians in Seattle. I believe we're one of the biggest employers for in the biotech or biopharma industry in that region. Most of our colleagues actually remained at Pfizer Inc., which is just a testament to our culture. And the success of the integration. A number of programs have started and been accelerated, including, as you've seen, the readout for 303 and 304 for PADCEP. We are planning an additional phase three study for PADCEP. It'll start later this year. It's an important study for us and for patients because that is to a study to potentially replace cystectomy. Which as you know leads to significant morbidity and mortality. We also accelerate a number of other programs into phase three including SV with two phase three studies ongoing and additional phase three that's study that's gonna start. PD-L1B and another phase three program ongoing in non-small cell lung cancer. And a number of phase one ADCs that's differentiated, including using the integrin beta-six antigen as a marker with new payloads including topo two and different new orastatin-based pilots. So integration overall, Seagen going very, very well. Regarding 4404, it is a differentiated molecule. What we've seen in the preclinical data was a hundredfold increase for the affin”